Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

about

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

Item

http://www.wikidata.org/entity/Q47595176

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@en

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@nl

type

Item

label

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@en

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@nl

prefLabel

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@en

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@nl

P1476

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.

@en

P2093

Chung-Feng Huang

http://www.w3.org/2001/XMLSchema#string

Ming-Lung Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Extrahepatic manifestations of chronic hepatitis C virus infection

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Sofosbuvir for previously untreated chronic hepatitis C infection

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

P304

1867-1874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1400010

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29086615

http://www.w3.org/2001/XMLSchema#string